TYRA Biosciences
NASDAQ: TYRACarlsbad, US · Delaware corporation · 4 known investors
Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers. The company operates in the biotech/pharmaceutical drug development space.
BiotechHealthtech
Founders & leadership
TH
Todd Harris, Ph.D.Founder
HT
Hiroomi Tada, M.D., Ph.D.Executive
DB
Daniel BensenExecutive
AF
Alan FuhrmanExecutive
Board
RM
NK
MM
Melissa McCracken, Ph.D.Board director
SS
Sid Subramony, Ph.D.Board director
JS
Jake Simson, Ph.D.Board director
IC
Isan Chen, M.D.Board director
RV
Rehan VerjeeBoard director
GK
Gilla Kaplan, Ph.D.Board director
Investors · 4
Reported raises · per SEC filings
Form D private placements$200M disclosed across 1 round · 2024
▶$200MraisedFeb 2024 · 21 investors · BiotechnologyRule 506(b)
▶$200MraisedFeb 2024 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Robert MoreDirector
- Hiroomi Tada, M.D., Ph.D.Executive Officer
- Isan Chen, M.D.Director
- Daniel BensenExecutive Officer
- Nina KjellsonDirector
- Alan FuhrmanExecutive Officer
- Rehan VerjeeDirector
- Melissa McCracken, Ph.D.Director
- Sid Subramony, Ph.D.Director
- Gilla Kaplan, Ph.D.Director
- Jake Simson, Ph.D.Director
- Todd Harris, Ph.D.Executive Officer, Director
- Offering amount
- $200M
- Amount sold
- $200M
- First sale
- Feb 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapAtara Biotherapeutics29 shared keywordsAtara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease. The company focuses on next-generation cell-based therapies designed for patients worldwide.
TradingView23 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Seeking Alpha23 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Companies competing with TYRA Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does TYRA Biosciences do?
- Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers. The company operates in the biotech/pharmaceutical drug development space.
- Who founded TYRA Biosciences?
- TYRA Biosciences was founded by Todd Harris, Ph.D..
- Who are TYRA Biosciences's investors?
- TYRA Biosciences's investors include Alta Partners, BioBrit, Nextech Invest, Canaan Partners.
- How much funding has TYRA Biosciences raised?
- TYRA Biosciences has disclosed $200M raised across 1 round.
- Where is TYRA Biosciences headquartered?
- TYRA Biosciences is headquartered in Carlsbad, US.